IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER

被引:8
作者
Aguloglu, Nursin [1 ]
Aksu, Aysegul [1 ]
Akyol, Murat [1 ]
Katgi, Nuran [1 ]
Doksoz, Tugce Ciftci [1 ]
机构
[1] Bahcesehir Cam & Sakura Hastanesi, Istanbul, Turkey
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2022年 / 61卷 / 06期
关键词
18F-FDG-PET; CT; Lung cancer; Textural analysis; EGFR; ALK; IMAGING PHENOTYPES; SOMATIC MUTATIONS; ADENOCARCINOMA;
D O I
10.1055/a-1868-4918
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Identification of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutation types is of great importance before treatment with tyrosine kinase inhibitors (TKIs). Radiomics is a new strategy for noninvasively predicting the genetic status of cancer. We aimed to evaluate the predictive power of 18F-FDG PET/CT-based radiomic features for mutational status before treatment in non-small cell lung cancer (NSCLC) and to develop a predictive model based on radiomic features. Methods Images of patients who underwent 18F-FDG PET/CT for initial staging with the diagnosis of NSCLC between January 2015 and July 2020 were evaluated using LIFEx software. The region of interest (ROI) of the primary tumor was established and volumetric and textural features were obtained. Clinical data and radiomic data were evaluated with machine learning (ML) algorithms to create a model. Results For EGFR mutation prediction, the most successful machine learning algorithm obtained with GLZLM_GLNU and clinical data was Naive Bayes (AUC: 0.751, MCC: 0.347, acc: 71.4%). For ALK rearrangement prediction, the most successful machine learning algorithm obtained with GLCM_correlation, GLZLM_LZHGE and clinical data was evaluated as Naive Bayes (AUC: 0.682, MCC: 0.221, acc: 77.4%). Conclusions In our study, we created prediction models based on radiomic analysis of 18F-FDG PET/CT images. Tissue analysis with ML algorithms are non-invasive methods for predicting ALK rearrangement and EGFR mutation status in NSCLC, which may be useful for targeted therapy selection in a clinical setting.
引用
收藏
页码:433 / 439
页数:7
相关论文
共 50 条
  • [21] Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer
    Shi, Aiqi
    Wang, Jianling
    Wang, Yuzhu
    Guo, Guorong
    Fan, Chouchou
    Liu, Jiangyan
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (04) : 393 - 400
  • [22] Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer
    Can, Canan
    Kepenek, Ferat
    Komek, Halil
    Gundogan, Cihan
    Kaplan, Ihsan
    Tasdemir, Bekir
    Guzel, Yunus
    Aguloglu, Nursin
    Karaoglan, Huseyin
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (10) : 1084 - 1091
  • [23] Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Schaarschmidt, Benedikt M.
    Grueneisen, Johannes
    Metzenmacher, Martin
    Gomez, Benedikt
    Gauler, Thomas
    Roesel, Christian
    Heusch, Philipp
    Ruhlmann, Verena
    Umutlu, Lale
    Antoch, Gerald
    Buchbender, Christian
    EUROPEAN RADIOLOGY, 2017, 27 (02) : 681 - 688
  • [24] Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Benedikt M. Schaarschmidt
    Johannes Grueneisen
    Martin Metzenmacher
    Benedikt Gomez
    Thomas Gauler
    Christian Roesel
    Philipp Heusch
    Verena Ruhlmann
    Lale Umutlu
    Gerald Antoch
    Christian Buchbender
    European Radiology, 2017, 27 : 681 - 688
  • [25] Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
    Hicks, Rodney J.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 31S - 42S
  • [26] An initial study on the comparison of diagnostic performance of 18F-FDG PET/MR and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer: Focus on pleural invasion
    Wang, Ma-li
    Zhang, He
    Yu, Hao-jun
    Tan, Hui
    Hu, Ling-zhi
    Kong, Han-jing
    Mao, Wu-jian
    Xiao, Jie
    Shi, Hong-cheng
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (01): : 16 - 23
  • [27] Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer
    Ma, Rong
    Zhao, Qian
    Zhao, Ren
    Li, Juan
    Wang, Yan-Yang
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (09) : 1026 - 1033
  • [28] Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer
    Zhuang, Fenghui
    Huang, Jia
    Wu, Junqi
    Xu, Long
    Zhang, Lei
    Li, Qiang
    Li, Chongwu
    Zhao, Yue
    Yang, Minglei
    Ma, Minjie
    She, Yunlang
    Chen, Hezhong
    Luo, Qingquan
    Zhao, Deping
    Chen, Chang
    LUNG CANCER, 2023, 178 : 20 - 27
  • [29] 18F-FDG PET/CT radiomics for prediction of lymphovascular invasion in patients with early stage non-small cell lung cancer
    Wang, Jie
    Zheng, Zhonghang
    Zhang, Yi
    Tan, Weiyue
    Li, Jing
    Xing, Ligang
    Sun, Xiaorong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer
    Pellegrino, Sara
    Fonti, Rosa
    Mazziotti, Emanuela
    Piccin, Luisa
    Mozzillo, Eleonora
    Iano, Vincenzo Dam
    Matano, Elide
    De Placido, Sabino
    Del Vecchi, Silvana
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (12) : 937 - 944